BridgeBio Pharma Inc (BBIO)
27.61
+0.38
(+1.40%)
USD |
NASDAQ |
Jun 18, 16:00
27.60
-0.01
(-0.04%)
After-Hours: 20:00
BridgeBio Pharma 1 Year Total Returns (Daily): 83.94% for June 18, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| June 18, 2024 | 83.94% |
| June 17, 2024 | 81.41% |
| June 14, 2024 | 64.95% |
| June 13, 2024 | 73.13% |
| June 12, 2024 | 81.40% |
| June 11, 2024 | 71.75% |
| June 10, 2024 | 73.94% |
| June 07, 2024 | 63.35% |
| June 06, 2024 | 69.08% |
| June 05, 2024 | 91.78% |
| June 04, 2024 | 90.25% |
| June 03, 2024 | 103.2% |
| May 31, 2024 | 104.2% |
| May 30, 2024 | 113.1% |
| May 29, 2024 | 100.8% |
| May 28, 2024 | 102.3% |
| May 24, 2024 | 110.2% |
| May 23, 2024 | 103.2% |
| May 22, 2024 | 113.5% |
| May 21, 2024 | 113.4% |
| May 20, 2024 | 115.2% |
| May 17, 2024 | 113.7% |
| May 16, 2024 | 120.3% |
| May 15, 2024 | 102.0% |
| May 14, 2024 | 113.7% |
| Date | Value |
|---|---|
| May 13, 2024 | 110.4% |
| May 10, 2024 | 110.4% |
| May 09, 2024 | 108.8% |
| May 08, 2024 | 104.9% |
| May 07, 2024 | 103.1% |
| May 06, 2024 | 105.3% |
| May 03, 2024 | 93.26% |
| May 02, 2024 | 98.71% |
| May 01, 2024 | 88.49% |
| April 30, 2024 | 76.45% |
| April 29, 2024 | 75.41% |
| April 26, 2024 | 74.11% |
| April 25, 2024 | 65.96% |
| April 24, 2024 | 64.56% |
| April 23, 2024 | 60.33% |
| April 22, 2024 | 57.87% |
| April 19, 2024 | 48.32% |
| April 18, 2024 | 64.69% |
| April 17, 2024 | 66.20% |
| April 16, 2024 | 71.23% |
| April 15, 2024 | 74.83% |
| April 12, 2024 | 76.75% |
| April 11, 2024 | 84.64% |
| April 10, 2024 | 81.59% |
| April 09, 2024 | 82.13% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-90.69%
Minimum
Jun 13 2022
543.5%
Maximum
Dec 27 2023
53.22%
Average
61.76%
Median
1 Year Total Returns (Daily) Benchmarks
| Alnylam Pharmaceuticals Inc | -23.67% |
| Pfizer Inc | -27.71% |
| Arcellx Inc | 50.31% |
| Biomarin Pharmaceutical Inc | -12.61% |
| Viking Therapeutics Inc | 140.2% |